181 related articles for article (PubMed ID: 19431095)
1. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.
Baron AT; Wilken JA; Haggstrom DE; Goodrich ST; Maihle NJ
IDrugs; 2009 May; 12(5):302-8. PubMed ID: 19431095
[TBL] [Abstract][Full Text] [Related]
2. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Pantel K; Krenkel S; Lück HJ; Neumann R; Keller T; Dittmer J; Jänicke F; Thomssen C
Anticancer Res; 2006; 26(2B):1479-87. PubMed ID: 16619561
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.
Lafky JM; Baron AT; Cora EM; Hillman DW; Suman VJ; Perez EA; Ingle JN; Maihle NJ
Cancer Res; 2005 Apr; 65(8):3059-62. PubMed ID: 15833834
[TBL] [Abstract][Full Text] [Related]
5. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
7. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
Le Tourneau C; Vidal L; Siu LL
Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
[TBL] [Abstract][Full Text] [Related]
8. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
Hudelist G; Köstler WJ; Gschwantler-Kaulich D; Czerwenka K; Kubista E; Müller R; Helmy S; Manavi M; Zielinski CC; Singer CF
Eur J Cancer; 2006 Jan; 42(2):186-92. PubMed ID: 16326100
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
Zampino MG; Magni E; Santoro L; Zorzino L; Dell'Orto P; Sonzogni A; Fazio N; Monfardini L; Chiappa A; Biffi R; de Braud F
Cancer Chemother Pharmacol; 2008 Dec; 63(1):139-48. PubMed ID: 18327586
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of growth factor signalling.
Wakeling AE
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S183-7. PubMed ID: 16113095
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
13. Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood.
Maramotti S; Paci M; Miccichè F; Ciarrocchi A; Cavazza A; De Bortoli M; Vaghi E; Formisano D; Canovi L; Sgarbi G; Bongarzone I
Lung Cancer; 2012 Jun; 76(3):332-8. PubMed ID: 22177532
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.
Lafky JM; Wilken JA; Baron AT; Maihle NJ
Biochim Biophys Acta; 2008 Apr; 1785(2):232-65. PubMed ID: 18291115
[TBL] [Abstract][Full Text] [Related]
15. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
16. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
17. The development of HKI-272 and related compounds for the treatment of cancer.
Wissner A; Mansour TS
Arch Pharm (Weinheim); 2008 Aug; 341(8):465-77. PubMed ID: 18493974
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the efficacy of hormonal agents with selected targeted agents.
Johnston SR
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
[TBL] [Abstract][Full Text] [Related]
19. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells.
Grunt TW; Wagner R; Grusch M; Berger W; Singer CF; Marian B; Zielinski CC; Lupu R
Biochem Biophys Res Commun; 2009 Jul; 385(3):454-9. PubMed ID: 19467222
[TBL] [Abstract][Full Text] [Related]
20. Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer.
Lococo F; Paci M; Rapicetta C; Rossi T; Sancisi V; Braglia L; Cavuto S; Bisagni A; Bongarzone I; Noonan DM; Albini A; Maramotti S
Int J Mol Sci; 2015 Aug; 16(8):19612-30. PubMed ID: 26295387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]